First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy
- First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs).
- SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally.
- Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and safety when used as an intradermal therapeutic vaccine.
Oegstgeest, The Netherlands, 08 November 2022 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to announce publication by Leiden University Medical Center (LUMC) of a phase 1 clinical study using ISA’s proprietary Amplivant® adjuvant and Synthetic Long Peptide (SLP®) therapeutic vaccine technology. The study was recently published in the Journal for ImmunoTherapy of Cancer. This open access paper is entitled ‘Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV16 positive (pre-)malignant lesions’ and can be found at: https://doi.org/10.1136/jitc-2022-005016.